Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies
Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
- Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
- The new Ascend Evo 600 magnet is easier to site, has reduced installation and operational costs, and has lower Helium consumption compared to previous 600 MHz magnets.
- In addition, Bruker expands the applications of its Fourier 80 platform, a benchtop 80 MHz Fourier Transform NMR with a high-performance permanent magnet that requires no cryogens or power.
- Here, the Fourier 80 system gathers reaction data for AI machine learning to formulate the rules and actions to guide process optimization.